These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31353322)
1. Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry. Djuric U; Lam KHB; Kao J; Batruch I; Jevtic S; Papaioannou MD; Diamandis P Mol Cell Proteomics; 2019 Oct; 18(10):2029-2043. PubMed ID: 31353322 [TBL] [Abstract][Full Text] [Related]
2. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111 [TBL] [Abstract][Full Text] [Related]
3. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]
15. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
16. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
17. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642 [TBL] [Abstract][Full Text] [Related]
18. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Gleize V; Alentorn A; Connen de Kérillis L; Labussière M; Nadaradjane AA; Mundwiller E; Ottolenghi C; Mangesius S; Rahimian A; Ducray F; ; Mokhtari K; Villa C; Sanson M Ann Neurol; 2015 Sep; 78(3):355-74. PubMed ID: 26017892 [TBL] [Abstract][Full Text] [Related]
19. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866 [TBL] [Abstract][Full Text] [Related]
20. Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors. Kitahama K; Iijima S; Sumiishi A; Hayashi A; Nagahama K; Saito K; Sasaki N; Kobayashi K; Shimizu S; Nagane M; Shibahara J Brain Tumor Pathol; 2021 Jan; 38(1):23-29. PubMed ID: 32989606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]